≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Follicular keratosis (Darier-White), including avohilmo

Endpoint Browser PheWeb

Q17_FOLLICULAR_KERATOSIS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Primary healthcare outpatient: ICD-10 — Q82.81
  • Hospital discharge: ICD-10 — Q82.81
  • Hospital discharge: ICD-9 — 7573K
  • Cause of death: ICD-10 — Q82.81
  • Cause of death: ICD-9 — 7573K

3 out of 7 registries used, show all original rules.

53

4. Check minimum number of events

None

53

5. Include endpoints

None

53

6. Filter based on genotype QC (FinnGen only)

50

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze
DF13

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 50 33 17
Unadjusted period prevalence (%) 0.01 0.01 0.01
Median age at first event (years) 50.51 48.37 54.65

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
53
Matched controls
530
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q82.81
ICD-10 Finland
Keratosis follicularis [Darier-White]
+∞
70.7
51
*
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
43.5
44.2
40
35
D05BB02
ATC
acitretin; oral
52.0
18.9
22
7
Q82.88
ICD-10 Finland
Other specified congenital malformations of skin
+∞
16.5
15
*
E0000UV, ,
ATC
10.6
13.3
43
153
Q82.80
ICD-10 Finland
Benign familial pemphigus [Hailey-Hailey]
+∞
13.0
12
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
19.2
13.0
20
16
D07BA04
ATC
hydrocortisone and antiseptics; topical
13.1
11.5
21
25
D02AE01
ATC
carbamide; topical
14.1
9.9
17
17
E000001, ,
ATC
5.5
8.6
25
74
D07AC01
ATC
betamethasone; topical
5.2
8.1
32
121
S29
ICPC
Skin symptom/complaint other
5.1
7.6
23
69
L30.9
ICD-10 Finland
Dermatitis, unspecified
4.9
7.2
23
72
D10BA01
ATC
isotretinoin; oral
11.5
6.7
12
13

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
hydrocortisone
S02BA01 [21605166]
2.1e+00
3.3e+00
1.0e+50
—
—
2.7e+00
—
cases:29.41%
controls:4.71%
cases:25.49%
controls:1.18%
cases:11.76%
controls:0.00%
—
—
—
—
cases:30.00%
controls:2.80%
—
—
15
24
36
486
13
6
38
504
6
0
45
510
—
—
15
14
35
486
—
hydrocortisone butyrate
D07AB02 [21602106]
2.0e+00
3.3e+00
1.0e+50
—
—
2.6e+00
—
cases:29.41%
controls:5.29%
cases:25.49%
controls:1.18%
cases:11.76%
controls:0.00%
—
—
—
—
cases:30.00%
controls:3.20%
—
—
15
27
36
483
13
6
38
504
6
0
45
510
—
—
15
16
35
484
—
hydrocortisone
C05AA01 [21601608]
2.0e+00
3.3e+00
1.0e+50
—
—
2.6e+00
—
cases:29.41%
controls:5.29%
cases:25.49%
controls:1.18%
cases:11.76%
controls:0.00%
—
—
—
—
cases:30.00%
controls:3.20%
—
—
15
27
36
483
13
6
38
504
6
0
45
510
—
—
15
16
35
484
—
hydrocortisone aceponate
D07AC16 [21602135]
2.0e+00
3.3e+00
1.0e+50
—
—
2.6e+00
—
cases:29.41%
controls:5.29%
cases:25.49%
controls:1.18%
cases:11.76%
controls:0.00%
—
—
—
—
cases:30.00%
controls:3.20%
—
—
15
27
36
483
13
6
38
504
6
0
45
510
—
—
15
16
35
484
—
hydrocortisone
D07AA02 [21602102]
2.0e+00
3.3e+00
1.0e+50
—
—
2.6e+00
—
cases:29.41%
controls:5.29%
cases:25.49%
controls:1.18%
cases:11.76%
controls:0.00%
—
—
—
—
cases:30.00%
controls:3.20%
—
—
15
27
36
483
13
6
38
504
6
0
45
510
—
—
15
16
35
484
—
hydrocortisone
A07EA02 [21600654]
2.0e+00
3.3e+00
1.0e+50
—
—
2.6e+00
—
cases:29.41%
controls:5.29%
cases:25.49%
controls:1.18%
cases:11.76%
controls:0.00%
—
—
—
—
cases:30.00%
controls:3.20%
—
—
15
27
36
483
13
6
38
504
6
0
45
510
—
—
15
16
35
484
—
hydrocortisone buteprate
D07AB11 [21602115]
2.0e+00
3.3e+00
1.0e+50
—
—
2.6e+00
—
cases:29.41%
controls:5.29%
cases:25.49%
controls:1.18%
cases:11.76%
controls:0.00%
—
—
—
—
cases:30.00%
controls:3.20%
—
—
15
27
36
483
13
6
38
504
6
0
45
510
—
—
15
16
35
484
—
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.5e+00
2.3e+00
—
1.0e+50
—
3.4e+00
—
cases:25.49%
controls:7.06%
cases:27.45%
controls:3.53%
—
—
cases:62.75%
controls:0.00%
—
—
cases:54.00%
controls:3.60%
—
—
13
36
38
474
14
18
37
492
—
32
0
19
510
—
27
18
23
482
—
combinations of corticosteroids
D07AB30 [21602118]
2.1e+00
2.3e+00
—
—
1.0e+50
2.3e+00
—
cases:45.10%
controls:9.22%
cases:27.45%
controls:3.73%
—
—
—
—
cases:15.69%
controls:0.00%
cases:34.00%
controls:4.80%
—
—
23
47
28
463
14
19
37
491
—
—
8
0
43
509
17
24
33
476
—
combinations of corticosteroids
D07XB30 [21602188]
2.1e+00
2.3e+00
—
—
1.0e+50
2.3e+00
—
cases:45.10%
controls:9.22%
cases:27.45%
controls:3.73%
—
—
—
—
cases:15.69%
controls:0.00%
cases:34.00%
controls:4.80%
—
—
23
47
28
463
14
19
37
491
—
—
8
0
43
509
17
24
33
476
—
triamcinolone and antiseptics
D07BB03 [21602150]
2.7e+00
—
1.0e+50
—
1.0e+50
3.6e+00
—
cases:19.61%
controls:1.57%
—
—
cases:11.76%
controls:0.00%
—
—
cases:11.76%
controls:0.00%
cases:28.00%
controls:1.00%
—
—
10
8
41
502
—
6
0
45
510
—
6
0
45
509
14
5
36
495
—
Case Management Agency
251B00000X [38004193]
2.4e-02
2.0e-01
8.6e-01
3.6e+00
8.2e-01
9.6e-02
—
cases:50.98%
controls:50.39%
cases:50.98%
controls:45.88%
cases:35.29%
controls:18.82%
cases:43.14%
controls:1.96%
cases:33.33%
controls:18.07%
cases:52.00%
controls:49.60%
—
—
26
257
25
253
26
234
25
276
18
96
33
414
22
10
29
500
17
92
34
417
26
248
24
252
—
hydrocortisone; local oral
A01AC03 [21600036]
2.8e+00
—
1.0e+50
—
1.0e+50
—
—
cases:13.73%
controls:0.98%
—
—
cases:9.80%
controls:0.00%
—
—
cases:9.80%
controls:0.00%
—
—
—
—
7
5
44
505
—
5
0
46
510
—
5
0
46
509
—
—
Pharmacy visit
OMOP4822462 [581458]
7.4e-01
8.2e-01
6.6e-01
2.7e+00
9.1e-01
1.0e+00
—
cases:94.12%
controls:88.43%
cases:90.20%
controls:80.20%
cases:56.86%
controls:40.59%
cases:21.57%
controls:1.76%
cases:62.75%
controls:40.47%
cases:92.00%
controls:80.20%
—
—
48
451
3
59
46
409
5
101
29
207
22
303
11
9
40
501
32
206
19
303
46
401
4
99
—
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
2.7e+00
—
1.0e+50
—
1.0e+50
—
—
cases:19.61%
controls:1.57%
—
—
cases:11.76%
controls:0.00%
—
—
cases:11.76%
controls:0.00%
—
—
—
—
10
8
41
502
—
6
0
45
510
—
6
0
45
509
—
—
chlorhexidine
S03AA04 [21605193]
2.7e+00
—
1.0e+50
—
1.0e+50
—
—
cases:19.61%
controls:1.57%
—
—
cases:11.76%
controls:0.00%
—
—
cases:11.76%
controls:0.00%
—
—
—
—
10
8
41
502
—
6
0
45
510
—
6
0
45
509
—
—
chlorhexidine
S02AA09 [21605155]
2.7e+00
—
1.0e+50
—
1.0e+50
—
—
cases:19.61%
controls:1.57%
—
—
cases:11.76%
controls:0.00%
—
—
cases:11.76%
controls:0.00%
—
—
—
—
10
8
41
502
—
6
0
45
510
—
6
0
45
509
—
—
hydrocortisone and antiseptics
D07BA04 [21602146]
2.7e+00
—
1.0e+50
—
1.0e+50
—
—
cases:19.61%
controls:1.57%
—
—
cases:11.76%
controls:0.00%
—
—
cases:11.76%
controls:0.00%
—
—
—
—
10
8
41
502
—
6
0
45
510
—
6
0
45
509
—
—
chlorhexidine
D09AA12 [21602275]
2.7e+00
—
1.0e+50
—
1.0e+50
—
—
cases:19.61%
controls:1.57%
—
—
cases:11.76%
controls:0.00%
—
—
cases:11.76%
controls:0.00%
—
—
—
—
10
8
41
502
—
6
0
45
510
—
6
0
45
509
—
—
hydrocortisone
D07XA01 [21602180]
2.7e+00
—
1.0e+50
—
1.0e+50
—
—
cases:19.61%
controls:1.57%
—
—
cases:11.76%
controls:0.00%
—
—
cases:11.76%
controls:0.00%
—
—
—
—
10
8
41
502
—
6
0
45
510
—
6
0
45
509
—
—
chlorhexidine, combinations
D08AC52 [21602208]
2.7e+00
—
1.0e+50
—
1.0e+50
—
—
cases:19.61%
controls:1.57%
—
—
cases:11.76%
controls:0.00%
—
—
cases:11.76%
controls:0.00%
—
—
—
—
10
8
41
502
—
6
0
45
510
—
6
0
45
509
—
—
hydrocortisone; oral, parenteral
H02AB09 [21602737]
2.6e+00
—
1.0e+50
—
—
—
—
cases:13.73%
controls:1.18%
—
—
cases:9.80%
controls:0.00%
—
—
—
—
—
—
—
—
7
6
44
504
—
5
0
46
510
—
—
—
—
cefalexin; oral
J01DB01 [21602870]
6.1e-01
1.1e+00
—
—
2.6e+00
8.1e-01
—
cases:41.18%
controls:27.65%
cases:21.57%
controls:8.43%
—
—
—
—
cases:13.73%
controls:1.18%
cases:20.00%
controls:10.00%
—
—
21
141
30
369
11
43
40
467
—
—
7
6
44
503
10
50
40
450
—
Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:10.00%
controls:1.00%
—
—
—
—
—
—
—
5
5
45
495
—
hydrocortisone and antiinfectives
S01CA03 [21603654]
2.4e+00
—
—
—
—
—
—
cases:9.80%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
5
5
46
505
—
—
—
—
—
—
Audiology
64 [38004489]
2.2e+00
—
—
—
—
—
—
cases:13.73%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
7
9
44
501
—
—
—
—
—
—
hydrocortisone and antiinfectives
S02CA03 [21605175]
2.0e+00
—
—
—
—
—
—
cases:13.73%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
44
499
—
—
—
—
—
—
hydrocortisone and antiinfectives
S03CA04 [21605208]
2.0e+00
—
—
—
—
—
—
cases:13.73%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
44
499
—
—
—
—
—
—
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
3.7e-01
6.0e-01
1.9e+00
—
—
6.6e-01
—
cases:33.33%
controls:25.69%
cases:27.45%
controls:17.25%
cases:17.65%
controls:3.14%
—
—
—
—
cases:30.00%
controls:18.20%
—
—
17
131
34
379
14
88
37
422
9
16
42
494
—
—
15
91
35
409
—
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
5.6e-01
3.3e-01
1.9e+00
—
—
8.2e-01
—
cases:33.33%
controls:22.16%
cases:21.57%
controls:16.47%
cases:15.69%
controls:2.75%
—
—
—
—
cases:32.00%
controls:17.20%
—
—
17
113
34
397
11
84
40
426
8
14
43
496
—
—
16
86
34
414
—
Monocytes [#/volume] in Blood
26484-6 [3001604]
—
1.2e+00
—
—
—
1.5e+00
—
—
—
cases:15.69%
controls:5.29%
—
—
—
—
—
—
cases:22.00%
controls:5.80%
—
—
—
8
27
43
483
—
—
—
11
29
39
471
—
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
0.0e+00
1.2e+00
—
—
—
1.5e+00
—
cases:9.80%
controls:9.80%
cases:15.69%
controls:5.49%
—
—
—
—
—
—
cases:22.00%
controls:6.00%
—
—
5
50
46
460
8
28
43
482
—
—
—
11
30
39
470
—
Basophils [#/volume] in Blood
26444-0 [3006315]
—
1.2e+00
—
—
—
1.4e+00
—
—
—
cases:15.69%
controls:5.49%
—
—
—
—
—
—
cases:22.00%
controls:6.20%
—
—
—
8
28
43
482
—
—
—
11
31
39
469
—
Eosinophils [#/volume] in Blood
26449-9 [3013115]
9.2e-02
1.2e+00
—
—
—
1.4e+00
—
cases:9.80%
controls:9.02%
cases:15.69%
controls:5.49%
—
—
—
—
—
—
cases:22.00%
controls:6.40%
—
—
5
46
46
464
8
28
43
482
—
—
—
11
32
39
468
—
Outpatient Visit
OP [9202]
3.3e-01
5.7e-01
-5.5e-02
—
8.5e-01
1.2e+00
—
cases:74.51%
controls:67.84%
cases:58.82%
controls:44.71%
cases:11.76%
controls:12.35%
—
—
cases:23.53%
controls:11.59%
cases:74.00%
controls:45.40%
—
—
38
346
13
164
30
228
21
282
6
63
45
447
—
12
59
39
450
37
227
13
273
—
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.00%
—
—
—
—
—
—
—
0
10
50
490
—
other preparations, combinations; ointment
C05AX03 [21601631]
1.8e+00
—
—
—
—
1.9e+00
—
cases:11.76%
controls:2.16%
—
—
—
—
—
—
—
—
cases:10.00%
controls:1.60%
—
—
6
11
45
499
—
—
—
—
5
8
45
492
—
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Body CT examination
JN4AD [2001310897]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
Pain general/multiple sites
A01 [2002000142]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
itraconazole; oral, parenteral
J02AC02 [21603081]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
Vaccination
SPAT1325 [2001700426]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.75%
—
—
—
—
—
—
—
—
—
—
—
—
0
14
51
496
—
—
—
—
—
—
Basophils/Leukocytes in Blood
30180-4 [3022096]
—
1.3e+00
—
—
—
1.4e+00
—
—
—
cases:13.73%
controls:4.31%
—
—
—
—
—
—
cases:18.00%
controls:5.00%
—
—
—
7
22
44
488
—
—
—
9
25
41
475
—
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
Diverticular disease of large intestine without perforation or abscess
K57.3 [45567316]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Scheduled procedure
ZXD10 [2001311387]
1.1e+00
—
—
—
—
—
—
cases:11.76%
controls:4.12%
—
—
—
—
—
—
—
—
—
—
—
—
6
21
45
489
—
—
—
—
—
—
Sedation and analgesia
WX002 [2001310758]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
Contraception oral
W11 [2002001211]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Cough
R05 [2002000886]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.35%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
51
498
—
—
—
—
—
—
citalopram; oral, parenteral
N06AB04 [21604712]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.55%
cases:0.00%
controls:1.37%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
0
13
51
497
0
7
51
503
—
—
—
0
5
50
495
—
betamethasone
A07EA04 [21600656]
9.5e-01
1.1e+00
—
—
—
—
—
cases:19.61%
controls:8.63%
cases:9.80%
controls:3.33%
—
—
—
—
—
—
—
—
—
—
10
44
41
466
5
17
46
493
—
—
—
—
—
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
4.4e-01
3.8e-02
—
—
—
2.2e-01
—
cases:37.25%
controls:27.65%
cases:19.61%
controls:19.02%
—
—
—
—
—
—
cases:24.00%
controls:20.20%
—
—
19
141
32
369
10
97
41
413
—
—
—
12
101
38
399
—
MCH [Entitic mass]
28539-5 [3035941]
2.5e-01
3.1e-01
1.4e+00
—
—
4.1e-01
—
cases:39.22%
controls:33.33%
cases:31.37%
controls:25.10%
cases:17.65%
controls:5.10%
—
—
—
—
cases:36.00%
controls:27.20%
—
—
20
170
31
340
16
128
35
382
9
26
42
484
—
—
18
136
32
364
—
cough suppressants and mucolytics
R05FB01 [21603441]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
499
—
—
—
—
—
—
Sleep disturbance
P06 [2002000803]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
5.9e-01
4.2e-01
—
—
—
4.3e-01
—
cases:31.37%
controls:20.20%
cases:23.53%
controls:16.86%
—
—
—
—
—
—
cases:26.00%
controls:18.60%
—
—
16
103
35
407
12
86
39
424
—
—
—
13
93
37
407
—
Neurosurgery
14 [38004459]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.55%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
0
13
51
497
0
6
51
504
—
—
—
0
8
50
492
—
pH of Specimen
17433-4 [3019225]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.96%
—
—
—
—
—
—
—
—
—
—
—
0
10
51
500
—
—
—
—
—
Medical doctor
Z2221 [2001311556]
1.3e+00
—
—
—
—
—
—
cases:11.76%
controls:3.53%
—
—
—
—
—
—
—
—
—
—
—
—
6
18
45
492
—
—
—
—
—
—
Eye symptom/complaint other
F29 [2002000412]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Hand/finger symptom/complaint
L12 [2002000636]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
Excision of other lesion extending through all layers of skin in head or neck
QAE10 [2001309784]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
51
502
—
—
—
—
—
—
hydroxocobalamin
V03AB33 [21605256]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.37%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
0
7
51
503
0
5
51
505
—
—
—
0
6
50
494
—
insulin (human); parenteral
A10AB01 [21600715]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:3.92%
cases:0.00%
controls:1.57%
—
—
cases:0.00%
controls:1.57%
cases:0.00%
controls:4.00%
—
—
—
0
20
51
490
0
8
51
502
—
0
8
51
501
0
20
50
480
—
Dental calculus supragingival
K03.64 [2000502689]
8.8e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:9.80%
controls:4.31%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
cases:0.00%
controls:2.00%
—
—
5
22
46
488
0
6
51
504
—
—
—
0
10
50
490
—
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
betamethasone
S02BA07 [21605169]
9.5e-01
1.1e+00
—
—
—
—
—
cases:19.61%
controls:8.63%
cases:9.80%
controls:3.33%
—
—
—
—
—
—
—
—
—
—
10
44
41
466
5
17
46
493
—
—
—
—
—
Infiltration anesthesia
WX110 [2001310767]
-5.3e-02
—
—
—
—
4.8e-01
—
cases:17.65%
controls:18.43%
—
—
—
—
—
—
—
—
cases:12.00%
controls:7.80%
—
—
9
94
42
416
—
—
—
—
6
39
44
461
—
metronidazole; oral, rectal
P01AB01 [21604857]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.20%
—
—
—
—
—
—
—
0
11
50
489
—
Osmolality of Urine
2695-5 [3026782]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
—
—
—
—
0
8
51
502
—
—
—
—
—
Examination of eyes and vision
Z01.0 [45566391]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
rizatriptan; oral
N02CC04 [21604379]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Opening and preparing the root canals, complicated
SGA03 [2001310381]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Extraction of tooth
EBA00 [2001301923]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
cromoglicic acid
S01GX01 [21605085]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
0
7
51
503
—
—
—
0
7
50
493
—
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
0
6
50
494
—
Laboratory Visit
OMOP4822461 [32036]
1.5e-01
2.1e-01
1.1e+00
—
7.0e-01
4.1e-01
—
cases:41.18%
controls:37.65%
cases:37.25%
controls:32.55%
cases:25.49%
controls:10.20%
—
—
cases:19.61%
controls:10.81%
cases:44.00%
controls:34.20%
—
—
21
192
30
318
19
166
32
344
13
52
38
458
—
10
55
41
454
22
171
28
329
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: Unspecified
SMOKING-2-2-0 [2002330110]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
temazepam; oral
N05CD07 [21604642]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
0
5
51
505
—
—
—
0
5
50
495
—
Menopausal and female climacteric states
N95.1 [45548683]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
beclometasone; nasal
R01AD01 [21605043]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.76%
cases:0.00%
controls:1.37%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
0
9
51
501
0
7
51
503
—
—
—
0
5
50
495
—
Thorax X-ray examination
GD1AA [2001303617]
7.9e-01
—
—
—
—
—
—
cases:11.76%
controls:5.69%
—
—
—
—
—
—
—
—
—
—
—
—
6
29
45
481
—
—
—
—
—
—
Emergency Room Visit
ER [9203]
3.9e-01
6.5e-01
—
—
—
2.4e-01
—
cases:35.29%
controls:27.06%
cases:15.69%
controls:8.82%
—
—
—
—
—
—
cases:10.00%
controls:8.00%
—
—
18
138
33
372
8
45
43
465
—
—
—
5
40
45
460
—
Multiple sclerosis
G35 [45571794]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
0
6
51
504
0
6
51
504
—
—
—
0
6
50
494
—
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.37%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
7
51
503
0
5
51
505
—
—
—
—
—
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
0
9
51
501
—
—
—
—
—
Abnormal findings in specimens from female genital organs, abnormal cytological findings
R87.6 [45558487]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Aid fitting and borrowing and monitoring of use
SPAT1230 [2001700331]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
PEF monitoring instruction
SPAT1058 [2001700159]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
501
—
—
—
—
—
—
Follitropin [Units/volume] in Serum or Plasma
15067-2 [3023323]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
gabapentin; oral
N02BF01 [955005]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.94%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
0
15
51
495
0
5
51
505
—
—
—
0
7
50
493
—
One-surface restoration
SFA10 [2001310358]
-7.3e-02
—
-1.0e+50
—
—
—
—
cases:11.76%
controls:12.55%
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
6
64
45
446
—
0
7
51
503
—
—
—
—
celecoxib
L01XX33 [21603805]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
7.9e-01
—
—
—
—
—
—
cases:9.80%
controls:4.71%
—
—
—
—
—
—
—
—
—
—
—
—
5
24
46
486
—
—
—
—
—
—
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
C50.41 [2000501002]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
0
5
51
505
—
—
—
0
5
50
495
—
Inpatient Hospital
21 [8717]
6.8e-01
1.0e+00
—
—
—
4.5e-01
—
cases:43.14%
controls:27.84%
cases:19.61%
controls:8.24%
—
—
—
—
—
—
cases:12.00%
controls:8.00%
—
—
22
142
29
368
10
42
41
468
—
—
—
6
40
44
460
—
estriol; oral, parenteral, vaginal
G03CA04 [21602518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
Preventive oral health care, short
SCA01 [2001310302]
1.1e+00
—
—
—
—
—
—
cases:9.80%
controls:3.33%
—
—
—
—
—
—
—
—
—
—
—
—
5
17
46
493
—
—
—
—
—
—
Spondylolisthesis
M43.1 [45606219]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
1.2e+00
—
—
—
—
-1.0e+50
—
cases:13.73%
controls:4.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
7
23
44
487
—
—
—
—
0
7
50
493
—
Sexual health counselling
SPAT1308 [2001700409]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.57%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
8
51
502
0
5
51
505
—
—
—
—
—
Routine postpartum follow-up
Z39.2 [45547306]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
—
1.0e+50
—
—
—
—
—
—
—
cases:9.80%
controls:0.00%
—
—
—
—
—
—
—
—
—
—
—
5
0
46
510
—
—
—
—
—
omeprazole; oral, parenteral
A02BC01 [21600096]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
0
7
51
503
—
—
—
0
6
50
494
—
pH of Venous blood
2746-6 [3012544]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
Psychologist
Z2445 [2001311558]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
No procedures
SPAT1301 [2001700402]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:4.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
21
51
489
—
—
—
—
—
—
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
INR in Blood by Coagulation assay
34714-6 [3032080]
3.6e-01
—
—
—
—
—
—
cases:9.80%
controls:7.06%
—
—
—
—
—
—
—
—
—
—
—
—
5
36
46
474
—
—
—
—
—
—
hydrochlorothiazide; oral
C03AA03 [21601466]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
0
5
51
504
—
—
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
1.7e-01
7.0e-01
—
—
—
4.1e-01
—
cases:17.65%
controls:15.29%
cases:17.65%
controls:9.61%
—
—
—
—
—
—
cases:16.00%
controls:11.20%
—
—
9
78
42
432
9
49
42
461
—
—
—
8
56
42
444
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.57%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
8
51
502
0
5
51
505
—
—
—
—
—
One hour or less
ZXE00 [2001311394]
1.1e+00
—
—
—
—
—
—
cases:11.76%
controls:4.31%
—
—
—
—
—
—
—
—
—
—
—
—
6
22
45
488
—
—
—
—
—
—
Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.98%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
5
51
505
0
5
51
505
—
—
—
—
—
dextromethorphan, combinations; oral
N07XX59 [43534835]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
499
—
—
—
—
—
—
felodipine; oral
C08CA02 [21601748]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
0
6
51
504
—
—
—
—
0
6
50
494
—
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Sinus symptom/complaint
R09 [2002000890]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Treatment plan or consultation
WZC00 [2001310885]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
quetiapine; oral
N05AH04 [21604544]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:5.10%
cases:0.00%
controls:3.73%
—
—
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:2.60%
—
—
0
26
51
484
0
19
51
491
—
—
0
6
51
503
0
13
50
487
—
fluticasone; nasal
R01AD08 [21605050]
4.7e-01
—
—
—
—
—
—
cases:15.69%
controls:10.39%
—
—
—
—
—
—
—
—
—
—
—
—
8
53
43
457
—
—
—
—
—
—
dexamethasone; oral, parenteral
H02AB02 [21602730]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection
94500-6 [706163]
9.2e-02
—
—
—
-1.0e+50
9.0e-01
—
cases:9.80%
controls:9.02%
—
—
—
—
—
—
cases:0.00%
controls:1.77%
cases:14.00%
controls:6.20%
—
—
5
46
46
464
—
—
—
0
9
51
500
7
31
43
469
—
Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay
5257-1 [3010521]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
dexamethasone
S03BA01 [21605201]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
0
6
50
494
—
Fever
A03 [2002000144]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Internal Medicine
11 [38004456]
3.0e-01
—
—
—
—
—
—
cases:21.57%
controls:16.86%
—
—
—
—
—
—
—
—
—
—
—
—
11
86
40
424
—
—
—
—
—
—
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
-8.0e-02
—
—
—
—
—
—
cases:13.73%
controls:14.71%
—
—
—
—
—
—
—
—
—
—
—
—
7
75
44
435
—
—
—
—
—
—
Telephone prescription or other care instructions
WZB00 [2001310884]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
0
7
51
503
—
—
—
0
7
50
493
—
dexamethasone
S01BA01 [21603618]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
0
6
50
494
—
naproxen; oral, rectal
M01AE02 [21603968]
-1.7e-01
—
—
—
—
-1.0e+50
—
cases:9.80%
controls:11.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
5
58
46
452
—
—
—
—
0
8
50
492
—
Hypothyroidism, unspecified
E03.9 [45537945]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
Calculus of ureter
N20.1 [45582395]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
long-acting sulfonamides - combinations
J01ED20 [21602959]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
499
—
—
—
—
—
—
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.35%
—
—
—
—
—
—
—
—
—
—
—
0
12
51
498
—
—
—
—
—
Orthopedic Surgery
20 [38004465]
3.5e-01
—
—
—
—
—
—
cases:15.69%
controls:11.57%
—
—
—
—
—
—
—
—
—
—
—
—
8
59
43
451
—
—
—
—
—
—
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
diphenhydramine, combinations
R06AA52 [21603454]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
499
—
—
—
—
—
—
Elevated blood pressure
K85 [2002000612]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.98%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
5
51
505
0
5
51
505
—
—
—
—
—
esomeprazole; oral, parenteral
A02BC05 [21600100]
5.4e-01
—
—
—
—
—
—
cases:15.69%
controls:9.80%
—
—
—
—
—
—
—
—
—
—
—
—
8
50
43
460
—
—
—
—
—
—
insulin lispro; parenteral
A10AD04 [21600732]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:2.94%
cases:0.00%
controls:2.55%
cases:0.00%
controls:0.98%
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:3.00%
—
—
0
15
51
495
0
13
51
497
0
5
51
505
—
0
6
51
503
0
15
50
485
—
Lysozyme [Mass/volume] in Serum or Plasma
2589-0 [3012110]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
7.0e-01
—
—
—
—
—
—
cases:9.80%
controls:5.10%
—
—
—
—
—
—
—
—
—
—
—
—
5
26
46
484
—
—
—
—
—
—
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
hypromellose
S01KA02 [21605115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.94%
—
—
—
—
—
—
—
—
—
—
—
—
0
15
51
495
—
—
—
—
—
—
Obesity due to excess calories
E66.01 [2000501501]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
0
5
51
505
—
—
—
—
0
7
50
493
—
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
4.3e-01
7.7e-01
—
—
—
—
—
cases:23.53%
controls:16.67%
cases:17.65%
controls:9.02%
—
—
—
—
—
—
—
—
—
—
12
85
39
425
9
46
42
464
—
—
—
—
—
Hypertension uncomplicated
K86 [2002000613]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
501
—
—
—
—
—
—
levofloxacin
S01AE05 [43534860]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
1.9e-01
7.2e-01
—
—
—
1.2e+00
—
cases:9.80%
controls:8.24%
cases:11.76%
controls:6.08%
—
—
—
—
—
—
cases:20.00%
controls:7.00%
—
—
5
42
46
468
6
31
45
479
—
—
—
10
35
40
465
—
Calculus of gallbladder without cholecystitis
K80.2 [45552951]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
51
502
—
—
—
—
—
—
Aortic (valve) stenosis
I35.0 [45576869]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Hemoglobin.gastrointestinal [Presence] in Stool
2335-8 [3016251]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
Injury of muscle(s) and tendon(s) of the rotator cuff of shoulder
S46.0 [45544769]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
lercanidipine; oral
C08CA13 [21601759]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
cases:0.00%
controls:1.60%
—
—
—
—
0
5
51
505
—
—
0
8
50
492
—
More than one and less than three hours
ZXE10 [2001311401]
6.3e-01
—
—
—
—
—
—
cases:9.80%
controls:5.49%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
46
482
—
—
—
—
—
—
Depressive episode, unspecified
F32.9 [45571760]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
501
—
—
—
—
—
—
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
8.1e-01
4.0e-01
—
—
—
8.4e-01
—
cases:31.37%
controls:16.86%
cases:11.76%
controls:8.24%
—
—
—
—
—
—
cases:16.00%
controls:7.60%
—
—
16
86
35
424
6
42
45
468
—
—
—
8
38
42
462
—
zolpidem; oral
N05CF02 [21604655]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
0
9
51
501
—
—
—
0
7
50
493
—
General anaesthesia
WX402 [2001310806]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
0
6
50
494
—
Respiratory symptom/complaint other
R29 [2002000898]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Respiratory and circulatory monitoring
WX700 [2001310817]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.5e-01
3.1e-01
1.3e+00
—
—
4.0e-01
—
cases:39.22%
controls:33.53%
cases:31.37%
controls:25.10%
cases:17.65%
controls:5.29%
—
—
—
—
cases:36.00%
controls:27.40%
—
—
20
171
31
339
16
128
35
382
9
27
42
483
—
—
18
137
32
363
—
hydroxychloroquine; oral
P01BA02 [21604889]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
0
6
51
504
—
—
—
—
0
7
50
493
—
Back symptom/complaint
L02 [2002000627]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
Dyspnoea
R06.0 [45558449]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
Pediatric Medicine
37 [38004477]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:3.92%
cases:0.00%
controls:2.16%
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
0
20
51
490
0
11
51
499
—
—
—
0
7
50
493
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
4.3e-01
3.8e-02
—
—
—
1.7e-01
—
cases:37.25%
controls:27.84%
cases:19.61%
controls:19.02%
—
—
—
—
—
—
cases:24.00%
controls:21.00%
—
—
19
142
32
368
10
97
41
413
—
—
—
12
105
38
395
—
Urgent procedure
ZXD05 [2001311386]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Counselling and guidance which enhance independent living
R2130 [2001310196]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
501
—
—
—
—
—
—
epinephrine; parenteral
C01CA24 [21600303]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
6
51
504
0
5
51
505
—
—
—
—
—
clarithromycin; oral, parenteral
J01FA09 [21602977]
9.1e-01
—
—
—
—
-1.0e+50
—
cases:11.76%
controls:5.10%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
6
26
45
484
—
—
—
—
0
8
50
492
—
Spinal stenosis
M48.0 [45557888]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
499
—
—
—
—
—
—
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
0
9
51
501
—
—
—
—
0
5
50
495
—
Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay
5253-0 [3027545]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Cough
R05 [45606792]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
0
6
50
494
—
Lateral epicondylitis
M77.1 [45572551]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
Tooth X-ray additional picture
EB1CA [2001301909]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
51
502
—
—
—
—
—
—
Microorganisms panel - Urine sediment
58435-9 [40761536]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
499
—
—
—
—
—
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
0
11
51
499
—
—
—
—
0
5
50
495
—
phenoxymethylpenicillin; oral
J01CE02 [21602842]
-8.0e-02
—
—
—
—
—
—
cases:13.73%
controls:14.71%
—
—
—
—
—
—
—
—
—
—
—
—
7
75
44
435
—
—
—
—
—
—
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
1.6e+00
—
—
—
—
—
—
cases:11.76%
controls:2.55%
—
—
—
—
—
—
—
—
—
—
—
—
6
13
45
497
—
—
—
—
—
—
encephalitis, tick borne, inactivated, whole virus
J07BA01 [21601331]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
fluticasone furoate; nasal
R01AD12 [21605053]
4.7e-01
—
—
—
—
—
—
cases:15.69%
controls:10.39%
—
—
—
—
—
—
—
—
—
—
—
—
8
53
43
457
—
—
—
—
—
—
Infectious Disease
44 [38004484]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
melatonin; oral
N05CH01 [21604659]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.35%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
0
12
51
498
—
—
—
—
0
8
50
492
—
celecoxib; oral
M01AH01 [21603992]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
Cardiology
6 [38004451]
3.0e-01
—
—
—
—
—
—
cases:9.80%
controls:7.45%
—
—
—
—
—
—
—
—
—
—
—
—
5
38
46
472
—
—
—
—
—
—
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
Gynaecological examination (general)(routine)
Z01.4 [45542395]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
0
11
51
499
—
—
—
—
0
8
50
492
—
insulin (human); parenteral
A10AD01 [21600729]
—
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:4.51%
cases:0.00%
controls:1.76%
—
—
cases:0.00%
controls:1.77%
cases:0.00%
controls:4.60%
—
—
—
0
23
51
487
0
9
51
501
—
0
9
51
500
0
23
50
477
—
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
1.4e+00
—
—
—
—
1.7e+00
—
cases:13.73%
controls:3.73%
—
—
—
—
—
—
—
—
cases:14.00%
controls:2.80%
—
—
7
19
44
491
—
—
—
—
7
14
43
486
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
501
—
—
—
—
—
—
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
1.2e+00
—
—
—
—
—
—
cases:11.76%
controls:3.92%
—
—
—
—
—
—
—
—
—
—
—
—
6
20
45
490
—
—
—
—
—
—
12 lead EKG panel
34534-8 [3044889]
6.5e-01
—
—
—
—
8.3e-01
—
cases:27.45%
controls:16.47%
—
—
—
—
—
—
—
—
cases:10.00%
controls:4.60%
—
—
14
84
37
426
—
—
—
—
5
23
45
477
—
Diabetes insulin dependent
T89 [2002001130]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.57%
cases:0.00%
controls:1.37%
—
—
—
—
—
—
cases:0.00%
controls:2.00%
—
—
0
8
51
502
0
7
51
503
—
—
—
0
10
50
490
—
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
499
—
—
—
—
—
—
Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma
14685-2 [3009035]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
Other complicated additional procedure necessary for restorative treatment
SFC92 [2001310370]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
CBC panel - Blood by Automated count
58410-2 [40761511]
3.7e-01
-2.7e-01
1.2e+00
—
—
5.1e-02
—
cases:37.25%
controls:29.02%
cases:13.73%
controls:17.25%
cases:9.80%
controls:3.14%
—
—
—
—
cases:20.00%
controls:19.20%
—
—
19
148
32
362
7
88
44
422
5
16
46
494
—
—
10
96
40
404
—
azithromycin; oral, parenteral
J01FA10 [21602978]
5.8e-02
—
—
—
—
—
—
cases:11.76%
controls:11.18%
—
—
—
—
—
—
—
—
—
—
—
—
6
57
45
453
—
—
—
—
—
—
cough suppressants and expectorants
R05FB02 [21603442]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
51
499
—
—
—
—
—
—
tolfenamic acid; oral, rectal
M01AG02 [21603988]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Senile nuclear cataract
H25.1 [45581628]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.37%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
0
7
51
503
0
6
51
504
—
—
—
0
5
50
495
—
Epithelial cells.non-squamous [#/volume] in Urine by Automated count
51485-1 [3030306]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.80%
—
—
—
—
—
—
—
0
9
50
491
—
Migraine with aura [classical migraine]
G43.1 [45562086]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.96%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
51
500
—
—
—
—
—
—
Immunohistochemistry procedure
117617002 [4035726]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
2.5e-01
9.3e-01
—
—
—
—
—
cases:11.76%
controls:9.41%
cases:9.80%
controls:4.12%
—
—
—
—
—
—
—
—
—
—
6
48
45
462
5
21
46
489
—
—
—
—
—
Other spondylosis with radiculopathy
M47.2 [45591850]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
51
502
—
—
—
—
—
—
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
2.5e-01
9.3e-01
—
—
—
—
—
cases:11.76%
controls:9.41%
cases:9.80%
controls:4.12%
—
—
—
—
—
—
—
—
—
—
6
48
45
462
5
21
46
489
—
—
—
—
—
Spirometry for bronchospasm with prolonged evaluation after bronchodilator
113016006 [4010399]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.76%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
9
51
501
0
5
51
505
—
—
—
—
—
cetirizine; oral
R06AE07 [21603497]
3.7e-01
1.3e+00
—
—
—
—
—
cases:11.76%
controls:8.43%
cases:11.76%
controls:3.33%
—
—
—
—
—
—
—
—
—
—
6
43
45
467
6
17
45
493
—
—
—
—
—
Health maint/preventive medicine
A98 [2002000231]
-2.8e-02
1.1e-02
—
—
—
5.0e-02
—
cases:29.41%
controls:30.00%
cases:23.53%
controls:23.33%
—
—
—
—
—
—
cases:28.00%
controls:27.00%
—
—
15
153
36
357
12
119
39
391
—
—
—
14
135
36
365
—
formoterol, glycopyrronium bromide and budesonide
R03AL11 [715850]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
0
6
50
494
—
Malignant neoplasm of breast
C50 [45571518]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Vascular Surgery
77 [38004496]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.4e-01
3.1e-01
1.3e+00
—
—
4.1e-01
—
cases:39.22%
controls:33.73%
cases:31.37%
controls:25.10%
cases:17.65%
controls:5.29%
—
—
—
—
cases:36.00%
controls:27.20%
—
—
20
172
31
338
16
128
35
382
9
27
42
483
—
—
18
136
32
364
—
Benign familial pemphigus [Hailey-Hailey]
Q82.80 [2000503508]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:12.00%
controls:0.00%
—
—
—
—
—
—
—
6
0
44
500
—
nebivolol; oral
C07AB12 [21601694]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
mirabegron; oral
G04BD12 [43534790]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.37%
cases:0.00%
controls:1.57%
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
0
7
51
503
0
8
51
502
—
—
—
0
7
50
493
—
Tissue Pathology biopsy report
66121-5 [40768804]
4.7e-01
—
—
—
—
—
—
cases:13.73%
controls:9.02%
—
—
—
—
—
—
—
—
—
—
—
—
7
46
44
464
—
—
—
—
—
—
Initiation, adjustment, discontinuation or repetition of medication
SPAT1253 [2001700354]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.40%
—
—
—
—
—
—
—
0
7
50
493
—
Outpatient Hospital
22 [8756]
1.5e-01
5.5e-01
—
—
—
—
—
cases:23.53%
controls:20.98%
cases:9.80%
controls:5.88%
—
—
—
—
—
—
—
—
—
—
12
107
39
403
5
30
46
480
—
—
—
—
—
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
290 [2001600222]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Basic examination of mouth
SAA02 [2001310275]
2.0e-01
—
—
—
—
—
—
cases:19.61%
controls:16.67%
—
—
—
—
—
—
—
—
—
—
—
—
10
85
41
425
—
—
—
—
—
—
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
1.7e-01
2.8e-01
-1.0e+50
—
-1.0e+50
4.0e-01
—
cases:41.18%
controls:37.06%
cases:23.53%
controls:18.82%
cases:0.00%
controls:2.75%
—
—
cases:0.00%
controls:3.54%
cases:26.00%
controls:19.00%
—
—
21
189
30
321
12
96
39
414
0
14
51
496
—
0
18
51
491
13
95
37
405
—
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
—
—
—
—
0
8
51
502
—
—
—
—
—
Radiotherapy after partial ablation of mammary gland
HA003 [2001303965]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
chloramphenicol
S01AA01 [21603554]
9.5e-01
—
—
—
—
—
—
cases:15.69%
controls:6.67%
—
—
—
—
—
—
—
—
—
—
—
—
8
34
43
476
—
—
—
—
—
—
tamsulosin; oral
G04CA02 [21602669]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
501
—
—
—
—
—
—
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
3.6e-01
-1.0e+50
—
—
—
—
—
cases:19.61%
controls:14.51%
cases:0.00%
controls:3.73%
—
—
—
—
—
—
—
—
—
—
10
74
41
436
0
19
51
491
—
—
—
—
—
prednisolone
A07EA01 [21600653]
6.2e-01
—
—
—
—
—
—
cases:19.61%
controls:11.57%
—
—
—
—
—
—
—
—
—
—
—
—
10
59
41
451
—
—
—
—
—
—
Emergency treatment
SGA01 [2001310379]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.75%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
14
51
496
0
5
51
505
—
—
—
—
—
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
6.9e-01
—
—
—
—
—
—
cases:11.76%
controls:6.27%
—
—
—
—
—
—
—
—
—
—
—
—
6
32
45
478
—
—
—
—
—
—
Primary total prosthetic replacement of knee joint without patellar part
NGB20 [2001308094]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Chest pain, unspecified
R07.4 [45558450]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
—
—
—
—
—
0
8
50
492
—
atorvastatin; oral
C10AA05 [21601860]
4.2e-01
—
—
—
—
5.3e-01
—
cases:11.76%
controls:8.04%
—
—
—
—
—
—
—
—
cases:12.00%
controls:7.40%
—
—
6
41
45
469
—
—
—
—
6
37
44
463
—
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
Shoulder lesion, unspecified
M75.9 [45557986]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Laparoscopic cholecystectomy
JKA21 [2001305294]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
Asthma
J45 [45596282]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
sildenafil; oral
G04BE03 [21602648]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.55%
cases:0.00%
controls:1.57%
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
0
13
51
497
0
8
51
502
—
—
—
0
8
50
492
—
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
—
1.3e+00
—
—
—
1.3e+00
—
—
—
cases:13.73%
controls:4.31%
—
—
—
—
—
—
cases:18.00%
controls:5.40%
—
—
—
7
22
44
488
—
—
—
9
27
41
473
—
Nonorganic insomnia
F51.0 [45552492]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Treatment-related counselling outside office
SPAT1249 [2001700350]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:3.53%
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
0
18
51
492
—
—
0
5
51
504
—
—
Knee X-ray examination without contrast
NG1AA [2001308049]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Body height measure
50373000 [4177340]
-5.1e-01
—
-1.0e+50
—
—
—
—
cases:19.61%
controls:28.82%
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
10
147
41
363
—
0
6
51
504
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 [2002330113]
3.4e-01
-1.0e+50
—
—
—
—
—
cases:11.76%
controls:8.63%
cases:0.00%
controls:1.96%
—
—
—
—
—
—
—
—
—
—
6
44
45
466
0
10
51
500
—
—
—
—
—
General Practice
1 [38004446]
5.2e-01
—
—
—
—
—
—
cases:9.80%
controls:6.08%
—
—
—
—
—
—
—
—
—
—
—
—
5
31
46
479
—
—
—
—
—
—
Comprehensive monitoring of chronic illness
SPAT1250 [2001700351]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:5.10%
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
—
—
—
0
26
51
484
0
8
51
502
—
—
—
—
—
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: current
SMOKING-1-1-1 [2002330115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
diclofenac
D11AX18 [21602355]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
—
—
—
0
5
50
495
—
Small restoration
SFA00 [2001310357]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
51
501
—
—
—
—
—
—
Dental examination
Z01.2 [45581002]
1.1e+00
—
—
—
—
-1.0e+50
—
cases:13.73%
controls:5.10%
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.00%
—
—
7
26
44
484
—
—
—
—
0
15
50
485
—
finasteride; oral
D11AX10 [21602350]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Diarrhoea
D11 [2002000310]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
51
502
—
—
—
—
—
—
ciclesonide; inhalant
R03BA08 [21603291]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.37%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
0
7
51
503
0
6
51
504
—
—
—
—
—
Body mass index
60621009 [4245997]
-5.0e-01
—
-1.0e+50
—
—
—
—
cases:19.61%
controls:28.63%
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
10
146
41
364
—
0
6
51
504
—
—
—
—
epinephrine
S01EA01 [21603673]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
6
51
504
0
5
51
505
—
—
—
—
—
Ophthalmology
18 [38004463]
3.5e-01
—
-1.0e+50
—
—
—
—
cases:15.69%
controls:11.57%
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
8
59
43
451
—
0
6
51
504
—
—
—
—
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
sulfadiazine and trimethoprim
J01EE02 [21602962]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
0
5
51
505
—
—
—
0
6
50
494
—
insulin aspart; parenteral
A10AD05 [21600733]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:3.33%
cases:0.00%
controls:3.33%
—
—
—
—
—
—
cases:0.00%
controls:3.40%
—
—
0
17
51
493
0
17
51
493
—
—
—
0
17
50
483
—
codeine and paracetamol
N02AJ06 [1123647]
3.3e-01
—
—
—
—
—
—
cases:17.65%
controls:13.33%
—
—
—
—
—
—
—
—
—
—
—
—
9
68
42
442
—
—
—
—
—
—
mometasone
D07AC13 [21602132]
1.3e+00
—
—
—
—
—
—
cases:13.73%
controls:4.31%
—
—
—
—
—
—
—
—
—
—
—
—
7
22
44
488
—
—
—
—
—
—
Trichilemmal cyst
L72.1 [45596386]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Palpitations
R00.2 [45558446]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
cases:0.00%
controls:1.60%
—
—
—
0
9
51
501
—
—
—
0
8
50
492
—
fusidic acid
D09AA02 [21602265]
1.1e+00
—
—
—
—
—
—
cases:9.80%
controls:3.53%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
46
492
—
—
—
—
—
—
desogestrel
G03AC09 [21602505]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.94%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
15
51
495
0
5
51
505
—
—
—
—
—
desonide
D07AB08 [21602112]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
—
0
6
50
494
—
Treatment of a patient needing special arrangements
WYA30 [2001310874]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Other chest pain
R07.3 [45597166]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
fusidic acid; ointment
D06AX01 [21602062]
1.1e+00
—
—
—
—
—
—
cases:9.80%
controls:3.53%
—
—
—
—
—
—
—
—
—
—
—
—
5
18
46
492
—
—
—
—
—
—
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.98%
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
0
5
51
505
0
5
51
505
—
—
—
—
—
chondroitin sulfate
M01AX25 [21604013]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.76%
—
—
—
—
—
—
—
—
—
—
—
0
9
51
501
—
—
—
—
—
Bacterial pneumonia, unspecified
J15.9 [45557621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
pseudoephedrine, combinations; oral
R01BA52 [21603213]
-5.5e-02
—
—
—
—
—
—
cases:11.76%
controls:12.35%
—
—
—
—
—
—
—
—
—
—
—
—
6
63
45
447
—
—
—
—
—
—
Pure hypercholesterolaemia
E78.01 [2000501514]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
Diabetes mellitus without mention of complication[DIABETES MELLITUS SINE COMPLICATIONE ,TYYPPI I]
2500B [2000402295]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
COVID-19, virus not identified
U07.2 [45756094]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.57%
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
0
8
51
502
0
6
51
504
—
—
—
—
—
Assessment of need for oral health care, standard
SAD01 [2001310287]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
1.3e-01
4.5e-01
—
—
—
1.0e-01
—
cases:21.57%
controls:19.41%
cases:17.65%
controls:11.96%
—
—
—
—
—
—
cases:14.00%
controls:12.80%
—
—
11
99
40
411
9
61
42
449
—
—
—
7
64
43
436
—
oxycodone and naloxone; oral
N02AA55 [21604265]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Contact with and exposure to other communicable diseases
Z20.8 [45542410]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
51
503
—
—
—
—
—
—
Connective tissue diseases, rheumatoid arthritis and comparable disease
202 [2001600200]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
—
Optical coherence tomography (OCT) of ocular fundus
CK2X4 [2001301456]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.98%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
51
505
—
—
—
—
—
—
Leukocytes [#/volume] in Urine
30405-5 [3018095]
7.9e-01
—
—
—
—
—
—
cases:9.80%
controls:4.71%
—
—
—
—
—
—
—
—
—
—
—
—
5
24
46
486
—
—
—
—
—
—
Deposits [accretions] on teeth betel
K03.65 [2000502690]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
—
—
—
—
—
—
—
—
—
—
—
0
6
51
504
—
—
—
—
—
Two-surface restoration
SFA20 [2001310359]
1.6e-01
-1.0e+50
—
—
—
—
—
cases:19.61%
controls:17.25%
cases:0.00%
controls:6.47%
—
—
—
—
—
—
—
—
—
—
10
88
41
422
0
33
51
477
—
—
—
—
—
insulin lispro; parenteral
A10AC04 [21600726]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:2.94%
cases:0.00%
controls:2.55%
cases:0.00%
controls:0.98%
—
—
cases:0.00%
controls:1.18%
cases:0.00%
controls:3.00%
—
—
0
15
51
495
0
13
51
497
0
5
51
505
—
0
6
51
503
0
15
50
485
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
13
21
7.82
5.83
1.5
1.3
—
—
—
0
0
17
52
4.34
5.29
3.5
1.6
—
—
—
0
0
23
115
2.77
3.13
1.4
1.3
20.14
23.64
iu/ml
—
7
48
11
38
3.38
2.61
1.2
1.2
41.00
151.34
u/ml
—
5
12
33
214
2.44
2.47
13.7
10.5
0.00
0.00
e9/l
0.50
26
173
38
266
2.51
2.35
9.9
7.0
0.21
0.19
e9/l
0.31
31
238
37
258
2.44
2.28
10.0
6.8
0.04
0.04
e9/l
0.19
29
226
37
258
2.44
2.28
10.1
6.7
0.55
0.59
e9/l
0.41
29
227
37
259
2.42
2.24
10.3
6.8
1.79
1.84
e9/l
0.18
30
232
33
233
2.10
1.79
10.6
7.0
59.29
56.91
%
0.63
33
221
38
287
2.14
1.68
11.7
10.7
4.47
4.01
e9/l
0.56
30
256
21
128
2.06
1.67
2.0
2.7
347.48
338.56
umol/l
0.15
21
115
18
107
2.03
1.51
3.3
2.4
7.79
8.58
e6/l
0.08
13
97
5
19
2.79
1.24
3.0
4.4
—
—
—
0
0
20
132
1.83
1.21
3.5
4.1
7.40
7.40
ph
0.20
14
96
27
197
1.76
1.16
2.5
1.9
—
—
—
0
0
7
32
2.36
1.13
3.0
10.8
23.34
25.12
mmol/l
—
7
32
18
118
1.80
1.10
4.2
2.9
—
—
—
0
0
19
127
1.77
1.09
4.3
3.0
0.21
0.35
e6/l
0.51
13
85
5
22
2.40
1.05
1.2
1.0
—
—
—
0
0
11
62
1.98
1.03
3.4
1.5
—
—
—
0
0
22
156
1.70
1.02
3.7
3.0
7.77
21.50
e6/l
0.99
15
113
7
36
2.08
1.01
7.1
5.1
—
0.17
—
0
12
0
28
0.00
1.01
0.0
3.9
—
—
—
0
0
24
177
1.65
0.95
4.4
3.8
53.20
11.43
e6/l
0.40
14
118
32
256
1.63
0.90
4.8
3.5
0.00
0.00
estimate
—
9
48
16
107
1.71
0.90
1.5
1.3
2.27
8.06
u/ml
—
7
48
23
170
1.62
0.89
7.8
6.5
—
—
—
0
0
13
82
1.78
0.88
3.6
2.3
460.22
532.59
mosm/kgh2o
—
8
69
32
257
1.62
0.88
4.8
3.6
0.00
0.00
estimate
—
9
48
37
310
1.64
0.84
5.4
4.3
—
40.73
—
0
11
25
191
1.58
0.83
5.0
3.3
0.00
0.03
estimate
—
8
40
21
154
1.60
0.83
2.4
3.2
—
—
—
0
0
32
260
1.58
0.81
4.8
3.6
0.00
0.00
estimate
—
8
46
23
174
1.57
0.79
1.9
2.1
109.35
97.55
pmol/l
—
6
90
20
147
1.58
0.77
6.0
7.3
—
—
—
0
0
7
38
1.97
0.77
2.7
8.8
1.11
1.16
mmol/l
—
7
38
7
39
1.91
0.76
7.4
5.5
—
0.15
—
0
13
15
103
1.64
0.75
1.7
2.0
—
—
—
0
0
7
40
1.86
0.75
7.1
4.8
—
0.69
—
0
16
18
130
1.58
0.74
4.2
2.9
—
—
estimate
—
0
0
5
26
2.02
0.72
3.4
11.5
0.56
0.70
%
—
5
26
7
42
1.77
0.72
5.7
4.3
—
0.47
—
0
17
5
27
1.94
0.70
3.4
11.2
1.02
1.77
%
—
5
27
26
207
1.50
0.69
3.4
3.2
5.82
6.17
ph
0.96
14
112
20
151
1.52
0.68
5.0
3.1
0.00
0.00
estimate
—
8
40
16
115
1.56
0.67
8.8
4.6
—
—
—
0
0
0
21
0.00
0.61
0.0
1.2
—
—
—
0
0
10
65
1.66
0.60
3.2
2.5
5.95
7.74
e9/l
—
10
58
6
36
1.75
0.59
6.8
3.0
—
—
—
0
0
6
37
1.70
0.58
1.3
1.5
—
—
—
0
0
10
67
1.61
0.54
1.2
1.4
—
—
—
0
0
17
130
1.45
0.53
1.2
1.2
0.64
1.81
u/ml
—
7
34
7
48
1.53
0.49
1.6
1.7
—
—
—
0
0
10
70
1.53
0.45
1.5
1.2
—
—
—
0
0
9
70
1.34
0.39
1.3
1.9
—
—
—
0
0
12
91
1.41
0.38
1.4
1.7
—
—
—
0
0
12
153
0.72
0.37
2.5
2.3
—
—
—
0
0
14
111
1.36
0.34
1.6
1.9
0.63
1.49
mg/l
0.76
14
88
15
122
1.32
0.31
5.3
4.1
—
—
—
0
0
15
123
1.31
0.29
1.3
1.4
2.30
2.55
g/l
—
9
76
16
135
1.27
0.25
4.6
3.5
0.00
0.00
estimate
—
8
48
5
41
1.24
0.22
3.8
8.7
—
—
—
0
0
5
42
1.21
0.22
4.0
8.5
12.10
7.69
mmol/l
—
5
42
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.8
—
—
—
0
0
0
12
0.00
0.21
0.0
3.3
—
55.82
—
0
12
0
13
0.00
0.21
0.0
1.7
—
0.11
—
0
7
0
14
0.00
0.20
0.0
2.7
—
63.03
—
0
14
7
59
1.21
0.19
5.1
7.5
105.00
103.68
mmol/l
—
7
59
6
53
1.15
0.09
1.0
1.6
—
—
—
0
0
7
67
1.05
0.08
1.6
1.5
—
—
—
0
0
8
76
1.06
0.08
1.5
1.7
—
—
—
0
0
45
440
1.15
0.07
6.4
5.4
1.85
1.82
mu/l
0.06
39
413
19
181
1.08
0.03
3.3
4.0
63.00
18.94
ng/l
0.39
12
117
14
147
0.94
0.02
1.4
1.4
—
—
—
0
0
11
109
1.01
0.00
3.2
4.8
1.05
2.12
ug/l
1.08
11
102
0
9
0.00
0.00
0.0
3.4
—
4.96
—
0
9
0
9
0.00
0.00
0.0
3.0
—
10.56
—
0
9
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
74.60
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
287.14
—
0
7
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
5
49
1.02
-0.00
2.2
1.4
—
—
—
0
0
5
54
0.92
-0.00
1.2
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
53
0.94
-0.00
1.6
1.7
—
—
—
0
0
22
220
1.00
-0.00
2.6
2.7
—
—
estimate
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
4.08
—
0
6
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
0.47
—
0
5
0
5
0.00
-0.00
0.0
2.2
—
24.60
—
0
5
7
71
0.98
-0.00
3.7
2.3
83.29
91.10
ug/g
—
7
58
0
6
0.00
-0.00
0.0
1.5
—
106.67
—
0
6
0
6
0.00
-0.00
0.0
6.7
—
10.02
—
0
6
22
220
1.00
-0.00
2.9
3.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
45.44
—
0
7
0
5
0.00
-0.00
0.0
1.6
—
138.38
—
0
5
0
6
0.00
-0.00
0.0
1.5
—
1.20
—
0
6
0
6
0.00
-0.00
0.0
1.7
—
-1.52
—
0
6

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: Q17_FOLLICULAR_KERATOSIS_WIDE – Follicular keratosis (Darier-White), including avohilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).